BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a average quality company.
The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kopran Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.4% | 9.5% | 9.5% | 5.3% | 8.7% | 8% | 13.6% | 5.6% | 9.4% | 11.4% | - |
| Value Creation Index ⓘ | -0.2 | -0.3 | -0.3 | -0.6 | -0.4 | -0.4 | 0.0 | -0.6 | -0.3 | -0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 326 | 187 | 182 | 154 | 197 | 179 | 223 | 205 | 273 | 337 | 296 |
| Sales YoY Gr. | - | -42.5% | -3.1% | -15.3% | 27.9% | -8.8% | 24.3% | -8.2% | 33.5% | 23.6% | - |
| Adj EPS ⓘ | 1.6 | 2.8 | 0.6 | 0 | 3.1 | 2.6 | 4.1 | 1.8 | 6.4 | 6.6 | 7.2 |
| YoY Gr. | - | 80% | -77.8% | -96.8% | 15250% | -14% | 54.2% | -54.8% | 249.5% | 1.9% | - |
| BVPS (₹) ⓘ | 39.6 | 43.5 | 46.5 | 47.6 | 50.5 | 53.1 | 57.1 | 78.6 | 82.1 | 86.3 | 86 |
| Adj Net Profit ⓘ | 6.4 | 12.1 | 2.7 | 0.1 | 13.3 | 11.4 | 17.6 | 8.9 | 31 | 31.6 | 35 |
| Cash Flow from Ops. ⓘ | 52.6 | 18.7 | 4.2 | 12.5 | 11.8 | 10 | 48.8 | -37.8 | 16.9 | 35 | - |
| Debt/CF from Ops. ⓘ | 0.7 | 1.8 | 13.4 | 4.2 | 4.2 | 4.6 | 0.3 | -1 | 1.7 | 0.7 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 0.4% | 11.4% | 14.8% | 23.6% | ||||
| Adj EPS ⓘ | 17.4% | 16.4% | 17.2% | 1.9% | ||||
| BVPSⓘ | 9% | 11.3% | 14.8% | 5.1% | ||||
| Share Price | 15.2% | 47.9% | -10.1% | -12.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.9 | 6.3 | 1.4 | 0 | 6.3 | 5.1 | 7.4 | 2.8 | 8 | 7.8 | 8.4 |
| Op. Profit Mgn % ⓘ | 9.7 | 13.3 | 9.6 | 4.7 | 11.8 | 13.1 | 13.5 | 7.5 | 10.4 | 10.9 | 14.3 |
| Net Profit Mgn % ⓘ | 2 | 6.4 | 1.5 | 0.1 | 6.8 | 6.4 | 7.9 | 4.3 | 11.4 | 9.4 | 11.7 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 221 | 267 | 188 | 233 | 186 | 229 | 187 | 236 | 231 | 204 | 97 |
| Cash Conv. Cycle ⓘ | 36 | 2 | 25 | 48 | 42 | 84 | 55 | 87 | 83 | 73 | 55 |
Return on Equity has increased versus last 3 years average to 8.30%
Sales growth is growing at healthy rate in last 3 years 14.84%
Net Profit is growing at healthy rate in last 3 years 17.19%
Sales growth is not so good in last 4 quarters at -4.01%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 7.2 | 11 |
| TTM Sales (₹ Cr.) | 296 | 636 |
| BVPS (₹.) ⓘ | 86 | 103.2 |
| Reserves (₹ Cr.) ⓘ | 379 | 450 |
| P/BV ⓘ | 2.51 | 2.10 |
| PE ⓘ | 30.10 | 19.73 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 198.05 / 369.20 |
| All Time Low / High (₹) | 6.40 / 558.84 |
| Market Cap (₹ Cr.) | 1,044 |
| Equity (₹ Cr.) | 48.3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 326 | 187 | 182 | 154 | 197 | 179 | 223 | 205 | 273 | 337 |
| Operating Expenses ⓘ | 294 | 162 | 164 | 146 | 174 | 156 | 193 | 189 | 245 | 301 |
| Manufacturing Costs | 43 | 22 | 26 | 28 | 30 | 29 | 31 | 37 | 39 | 45 |
| Material Costs | 194 | 103 | 95 | 77 | 102 | 86 | 121 | 107 | 156 | 205 |
| Employee Cost | 29 | 16 | 19 | 18 | 20 | 20 | 18 | 21 | 25 | 26 |
| Other Costs ⓘ | 28 | 22 | 24 | 23 | 21 | 21 | 23 | 25 | 25 | 25 |
| Operating Profit ⓘ | 32 | 25 | 17 | 7 | 23 | 23 | 30 | 15 | 28 | 37 |
| Operating Profit Margin (%) | 9.7% | 13.3% | 9.6% | 4.7% | 11.5% | 12.9% | 13.5% | 7.5% | 10.2% | 10.9% |
| Other Income ⓘ | 6 | 1 | 9 | 10 | 3 | 2 | 10 | 8 | 16 | 17 |
| Interest ⓘ | 13 | 10 | 10 | 7 | 5 | 6 | 4 | 3 | 3 | 5 |
| Depreciation ⓘ | 10 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 |
| Exceptional Items ⓘ | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 15 | 11 | 13 | 7 | 17 | 16 | 33 | 16 | 37 | 45 |
| Tax ⓘ | 0 | 0 | 5 | 2 | 4 | 5 | 9 | 4 | 6 | 10 |
| Profit After Tax | 15 | 11 | 9 | 5 | 13 | 11 | 23 | 12 | 31 | 35 |
| PAT Margin (%) | 4.8% | 6.1% | 4.7% | 3.1% | 6.6% | 6.3% | 10.5% | 5.7% | 11.4% | 10.3% |
| Adjusted EPS (₹) | 3.8 | 2.6 | 2.0 | 1.1 | 3.0 | 2.6 | 5.4 | 2.4 | 6.5 | 7.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 28% | 123% | 46% | 42% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 171 | 197 | 201 | 206 | 218 | 230 | 247 | 379 | 396 | 416 |
| Share Capital ⓘ | 50 | 52 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 |
| Reserves ⓘ | 122 | 145 | 158 | 162 | 175 | 186 | 204 | 331 | 347 | 368 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 26 | 29 | 50 | 45 | 41 | 36 | 16 | 37 | 28 | 23 |
| Long Term Debt | 8 | 22 | 28 | 22 | 22 | 10 | 2 | 2 | 2 | 2 |
| Short Term Debt | 18 | 7 | 22 | 24 | 19 | 27 | 13 | 35 | 26 | 20 |
| Trade Payables | 36 | 36 | 36 | 29 | 32 | 32 | 40 | 30 | 62 | 52 |
| Others Liabilities ⓘ | 41 | 18 | 19 | 17 | 24 | 28 | 22 | 19 | 20 | 21 |
| Total Liabilities ⓘ | 275 | 279 | 306 | 297 | 316 | 326 | 324 | 464 | 506 | 511 |
Fixed Assets | ||||||||||
| Gross Block | 78 | 83 | 43 | 45 | 51 | 56 | 65 | 68 | 73 | 82 |
| Accumulated Depreciation | 45 | 48 | 3 | 7 | 10 | 13 | 17 | 21 | 26 | 30 |
| Net Fixed Assetsⓘ | 33 | 35 | 39 | 38 | 42 | 43 | 47 | 46 | 47 | 52 |
| CWIP ⓘ | 0 | 0 | 4 | 8 | 7 | 7 | 3 | 3 | 4 | 5 |
| Investmentsⓘ | 46 | 156 | 157 | 157 | 158 | 158 | 159 | 259 | 260 | 261 |
| Inventories | 14 | 28 | 25 | 30 | 25 | 41 | 28 | 42 | 48 | 49 |
| Trade Receivables | 29 | 20 | 38 | 20 | 45 | 42 | 49 | 59 | 84 | 88 |
| Cash Equivalents | 4 | 4 | 2 | 2 | 1 | 1 | 3 | 3 | 3 | 7 |
| Others Assetsⓘ | 148 | 35 | 40 | 42 | 39 | 33 | 35 | 52 | 61 | 48 |
| Total Assets ⓘ | 275 | 279 | 306 | 297 | 316 | 326 | 324 | 464 | 506 | 511 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 53 | 19 | 4 | 12 | 12 | 10 | 49 | -38 | 17 | 35 |
| PBT ⓘ | 15 | 11 | 13 | 7 | 17 | 16 | 33 | 16 | 37 | 45 |
| Adjustment ⓘ | 22 | 13 | 16 | 6 | 3 | 12 | 7 | 4 | -9 | 3 |
| Changes in Working Capital ⓘ | 15 | -6 | -24 | 3 | -5 | -14 | 14 | -55 | -5 | -2 |
| Tax Paid ⓘ | 0 | 0 | -1 | -3 | -4 | -4 | -5 | -4 | -6 | -10 |
| Cash Flow From Investing Activity ⓘ | -10 | -4 | -9 | -2 | -4 | 1 | -9 | -100 | 10 | -6 |
| Capex | -11 | -5 | -12 | -5 | -6 | -5 | -4 | -3 | -6 | -10 |
| Net Investments | 1 | -1 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 |
| Others ⓘ | 1 | 3 | 3 | 4 | 1 | 5 | -2 | -97 | 16 | 4 |
| Cash Flow From Financing Activityⓘ | -43 | -15 | 5 | -11 | -7 | -11 | -40 | 138 | -26 | -24 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 126 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | -14 | 0 | 0 | 0 | -9 | 0 | 0 | 0 |
| Interest Paid ⓘ | -13 | -10 | -10 | -7 | -5 | -6 | -4 | -3 | -3 | -5 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -6 | -6 | -14 | -14 |
| Others ⓘ | -30 | -5 | 28 | -4 | -2 | -5 | -20 | 21 | -9 | -5 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 10.34 | 6.52 | 4.37 | 2.31 | 6.12 | 5.01 | 9.85 | 3.75 | 8.07 | 8.54 |
| ROCE (%) | 11.44 | 9.45 | 9.5 | 5.28 | 8.67 | 7.98 | 13.57 | 5.64 | 9.44 | 11.36 |
| Asset Turnover Ratio | 1.11 | 0.68 | 0.62 | 0.51 | 0.64 | 0.56 | 0.69 | 0.52 | 0.56 | 0.66 |
| PAT to CFO Conversion(x) | 3.53 | 1.73 | 0.44 | 2.4 | 0.92 | 0.91 | 2.13 | -3.17 | 0.55 | 1 | Working Capital Days |
| Receivable Days | 46 | 47 | 58 | 69 | 60 | 89 | 75 | 97 | 96 | 93 |
| Inventory Days | 37 | 41 | 53 | 65 | 51 | 68 | 56 | 62 | 60 | 53 |
| Payable Days | 68 | 128 | 137 | 154 | 109 | 134 | 106 | 119 | 107 | 102 |
The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.
Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.
Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.
Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.
The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.
KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.
Product range of the company includes:
Finished Dosage Forms
Active Pharmaceutical Ingredients
Achievements/ recognition:
Future plans:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
